Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2015

Open Access 01-12-2015 | Research

Trogocytic intercellular membrane exchanges among hematological tumors

Authors: Joel LeMaoult, Julien Caumartin, Marina Daouya, Magdalena Switala, Vera Rebmann, Bertrand Arnulf, Edgardo D Carosella

Published in: Journal of Hematology & Oncology | Issue 1/2015

Login to get access

Abstract

Trogocytosis is the transfer of plasma membrane fragments and the molecules they contain between one donor and one acceptor/acquirer cell. Through trogocytosis, acceptor cells temporarily display and use cell-surface molecules they do not express themselves, but borrow from other cells. Here, we investigated whether liquid tumors possessed a trogocytic capability, if immune escape molecules could be acquired by tumor cells, transferred between cells of the same tumor, and if this could benefit the tumor as a whole.
For this, we investigated trogocytosis in hematological cell lines and freshly isolated hematological tumor cells. We demonstrate that hematological tumor lines possess a trogocytic capability that allows them to capture membranes that contain the immune-inhibitory molecule HLA-G from allogeneic as well as from autologous sources. We further show that freshly isolated hematological tumor cells also possess these capabilities. This work reports for the first time the trogocytic capabilities of liquid tumor cells and introduces the notion of immune escape strategy sharing among tumor cells through trogocytosis of membrane-bound immune-inhibitory molecules.
Appendix
Available only for authorised users
Literature
1.
Liu X, Gu W, Li X. HLA-G regulates the invasive properties of JEG-3 choriocarcinoma cells by controlling STAT3 activation. Placenta. 2013;34(11):1044–52.PubMedCrossRef
2.
Wang JM, Zhao HX, Wang L, Gao ZY, Yao YQ. The human leukocyte antigen G promotes trophoblast fusion and beta-hCG production through the Erk1/2 pathway in human choriocarcinoma cell lines. Biochem Biophys Res Commun. 2013;434(3):460–5. Epub 2013/04/16.PubMedCrossRef
3.
Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990;248(4952):220–3. Epub 1990/04/13.PubMedCrossRef
4.
Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci U S A. 1997;94(21):11520–5.PubMedCentralPubMedCrossRef
5.
Mallet V, Blaschitz A, Crisa L, Schmitt C, Fournel S, King A, et al. HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83(+) dendritic cells expresses HLA-G as a membrane-bound and soluble protein. Int Immunol. 1999;11(6):889–98.PubMedCrossRef
6.
Cirulli V, Zalatan J, McMaster M, Prinsen R, Salomon DR, Ricordi C, et al. The Class I HLA Repertoire of Pancreatic Islets Comprises the Nonclassical Class Ib Antigen HLA-G. Diabetes. 2006;55(5):1214–22.PubMedCrossRef
7.
Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, et al. Human Leukocyte Antigen-G5 Secretion by Human Mesenchymal Stem Cells Is Required to Suppress T Lymphocyte and Natural Killer Function and to Induce CD4 + CD25highFOXP3+ Regulatory T Cells. Stem Cells. 2008;26(1):212–22.PubMedCrossRef
8.
Verloes A, Van de Velde H, LeMaoult J, Mateizel I, Cauffman G, Horn PA, et al. HLA-G expression in human embryonic stem cells and preimplantation embryos. J Immunol. 2011;186(4):2663–71. Epub 2011/01/21.PubMedCrossRef
9.
Lila N, Carpentier A, Amrein C, Khalil-Daher I, Dausset J, Carosella ED. Implication of HLA-G molecule in heart-graft acceptance. Lancet. 2000;355(9221):2138. Epub 2000/07/21.PubMedCrossRef
10.
Aractingi S, Briand N, Le Danff C, Viguier M, Bachelez H, Michel L, et al. HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells? Am J Pathol. 2001;159(1):71–7. Epub 2001/07/05.PubMedCentralPubMedCrossRef
11.
Lozano JM, Gonzalez R, Kindelan JM, Rouas-Freiss N, Caballos R, Dausset J, et al. Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule. AIDS. 2002;16(3):347–51. Epub 2002/02/09.PubMedCrossRef
12.
Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A. 1998;95(8):4510–5.PubMedCentralPubMedCrossRef
13.
Moreau P, Mouillot G, Rousseau P, Marcou C, Dausset J, Carosella ED. HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci U S A. 2003;100(3):1191–6.PubMedCentralPubMedCrossRef
14.
Lynge Nilsson L, Djurisic S, Hviid TV. Controlling the immunological crosstalk during conception and pregnancy: HLA-G in reproduction. Front Immunol. 2014;5:198.PubMedCentralPubMedCrossRef
15.
Jasinski-Bergner S, Mandelboim O, Seliger B. The Role of MicroRNAs in the Control of Innate Immune Response in Cancer. J Natl Cancer Inst Monogr. 2014;106(10):dju257.CrossRef
16.
Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci U S A. 1997;94(10):5249–54.PubMedCentralPubMedCrossRef
17.
Riteau B, Rouas-Freiss N, Menier C, Paul P, Dausset J, Carosella ED. HLA-G2, −G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol. 2001;166(8):5018–26. Epub 2001/04/06.PubMedCrossRef
18.
Rouas-Freiss N, Khalil-Daher I, Riteau B, Menier C, Paul P, Dausset J, et al. The immunotolerance role of HLA-G. Semin Cancer Biol. 1999;9(1):3–12. Epub 1999/03/27.PubMedCrossRef
19.
Park GM, Lee S, Park B, Kim E, Shin J, Cho K, et al. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun. 2004;313(3):606–11.PubMedCrossRef
20.
LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci U S A. 2004;101(18):7064–9.PubMedCentralPubMedCrossRef
21.
Bahri R, Hirsch F, Josse A, Rouas-Freiss N, Bidere N, Vasquez A, et al. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol. 2006;176(3):1331–9. Epub 2006/01/21.PubMedCrossRef
22.
Caumartin J, Favier B, Daouya M, Guillard C, Moreau P, Carosella ED, et al. Trogocytosis-based generation of suppressive NK cells. EMBO J. 2007;26(5):1423–33. Epub 2007/02/24.PubMedCentralPubMedCrossRef
23.
Ristich V, Liang S, Zhang W, Wu J, Horuzsko A. Tolerization of dendritic cells by HLA-G. Eur J Immunol. 2005;35(4):1133–42. Epub 2005/03/17.PubMedCrossRef
24.
Liang S, Ristich V, Arase H, Dausset J, Carosella ED, Horuzsko A. Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6–STAT3 signaling pathway. Proc Natl Acad Sci U S A. 2008;105(24):8357–62.PubMedCentralPubMedCrossRef
25.
Naji A, Le Rond S, Durrbach A, Krawice-Radanne I, Creput C, Daouya M, et al. CD3 + CD4low and CD3 + CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood. 2007;110(12):3936–48.PubMedCrossRef
26.
Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood. 2010;116(6):935–44. Epub 2010/05/08.PubMedCrossRef
27.
Agaugue S, Carosella ED, Rouas-Freiss N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood. 2011;117(26):7021–31. Epub 2011/04/13.PubMedCrossRef
28.
Ibrahim EC, Guerra N, Lacombe MJ, Angevin E, Chouaib S, Carosella ED, et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res. 2001;61(18):6838–45. Epub 2001/09/18.PubMed
29.
Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol. 2001;159(3):817–24. Epub 2001/09/11.PubMedCentralPubMedCrossRef
30.
Polakova K, Russ G. Expression of the non-classical HLA-G antigen in tumor cell lines is extremely restricted. Neoplasma. 2000;47(6):342–8. Epub 2001/03/27.PubMed
31.
Davies B, Hiby S, Gardner L, Loke YW, King A. HLA-G expression by tumors. Am J Reprod Immunol. 2001;45(2):103–7. Epub 2001/02/24.PubMedCrossRef
32.
Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, et al. Expression of HLA G in human tumors is not a frequent event. Int J Cancer. 1999;81(4):512–8. Epub 1999/05/04.PubMedCrossRef
33.
McMaster M, Zhou Y, Shorter S, Kapasi K, Geraghty D, Lim KH, et al. HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylation. J Immunol. 1998;160(12):5922–8. Epub 1998/06/24.PubMed
34.
Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol. 2002;196(3):266–74. Epub 2002/02/22.PubMedCrossRef
35.
Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood. 2002;99(2):609–17. Epub 2002/01/10.PubMedCrossRef
36.
Yan WH. Human leukocyte antigen-G in cancer: are they clinically relevant? Cancer Lett. 2011;311(2):123–30. Epub 2011/08/17.PubMedCrossRef
37.
38.
Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 2005;105(4):1694–8. Epub 2004/10/07.PubMedCrossRef
39.
Rebmann V, Wagner S, Grosse-Wilde H. HLA-G expression in malignant melanoma. Semin Cancer Biol. 2007;17(6):422–9. Epub 2007/08/11.PubMedCrossRef
40.
LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood. 2007;109(5):2040–8. Epub 2006/11/02.PubMedCrossRef
41.
Davis DM. Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response. Nat Rev Immunol. 2007;7(3):238–43. Epub 2007/02/10.PubMedCrossRef
42.
43.
HoWangYin KY, Caumartin J, Favier B, Daouya M, Yaghi L, Carosella ED, et al. Proper regrafting of Ig-like transcript 2 after trogocytosis allows a functional cell-cell transfer of sensitivity. J Immunol. 2011;186(4):2210–8. Epub 2011/01/19.PubMedCrossRef
44.
He T, Zong S, Wu X, Wei Y, Xiang J. CD4+ T cell acquisition of the bystander pMHC I colocalizing in the same immunological synapse comprising pMHC II and costimulatory CD40, CD54, CD80, OX40L, and 41BBL. Biochem Biophys Res Commun. 2007;362(4):822–8.PubMedCrossRef
45.
LeMaoult J, Caumartin J, Carosella ED. Exchanges of membrane patches (trogocytosis) split theoretical and actual functions of immune cells. Hum Immunol. 2007;68(4):240–3. Epub 2007/04/03.PubMedCrossRef
46.
Alegre E, Howangyin KY, Favier B, Baudhuin J, Lesport E, Daouya M, et al. Membrane redistributions through multi-intercellular exchanges and serial trogocytosis. Cell Res. 2010;20(11):1239–51. Epub 2010/09/30.PubMedCrossRef
47.
HoWangYin KY, Alegre E, Daouya M, Favier B, Carosella ED, LeMaoult J. Different functional outcomes of intercellular membrane transfers to monocytes and T cells. Cell Mol Life Sci. 2010;67(7):1133–45. Epub 2010/03/20.PubMedCrossRef
48.
Poupot M, Fournie JJ. Spontaneous membrane transfer through homotypic synapses between lymphoma cells. J Immunol. 2003;171(5):2517–23. Epub 2003/08/21.PubMedCrossRef
49.
LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J. 2005;19(6):662–4. Epub 2005/01/27.PubMed
50.
Aucher A, Magdeleine E, Joly E, Hudrisier D. Capture of plasma membrane fragments from target cells by trogocytosis requires signaling in T cells but not in B cells. Blood. 2008;111(12):5621–8. Epub 2008/04/03.PubMedCentralPubMedCrossRef
51.
Brown R, Kabani K, Favaloro J, Yang S, Ho PJ, Gibson J, et al. CD86+ or HLA-G+ myeloma cells are associated with poor prognosis and once acquired by trogocytosis create novel Tregacq cells. Blood. 2012;120(10):2055–63. Epub 2012/06/19.PubMedCrossRef
52.
Hudrisier D, Riond J, Garidou L, Duthoit C, Joly E. T cell activation correlates with an increased proportion of antigen among the materials acquired from target cells. Eur J Immunol. 2005;35(8):2284–94.PubMedCrossRef
53.
Rebmann V, Nuckel H, Duhrsen U, Grosse-Wilde H. HLA-G in B-chronic lymphocytic leukaemia: clinical relevance and functional implications. Semin Cancer Biol. 2007;17(6):430–5. Epub 2007/08/09.PubMedCrossRef
54.
Giannopoulos K, Dmoszynska A, Bojarska-Junak A, Schmitt M, Rolinski J. Expression of HLA-G in patients with B-cell chronic lymphocytic leukemia (B-CLL). Folia Histochem Cytobiol. 2008;46(4):457–60. Epub 2009/01/15.PubMed
55.
Erikci AA, Karagoz B, Ozyurt M, Ozturk A, Kilic S, Bilgi O. HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? Hematology. 2009;14(2):101–5. Epub 2009/03/21.PubMedCrossRef
56.
Wlasiuk P, Stec A, Piechnik A, Kaminska W, Dmoszynska A, Ksiazek A, et al. Expression of soluble HLA-G in multiple myeloma patients and patients with renal failure. Leuk Res. 2012;36(7):881–3. Epub 2012/03/17.PubMedCrossRef
57.
Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia. 2008;22(5):998–1006. Epub 2008/02/22.PubMedCrossRef
Metadata
Title
Trogocytic intercellular membrane exchanges among hematological tumors
Authors
Joel LeMaoult
Julien Caumartin
Marina Daouya
Magdalena Switala
Vera Rebmann
Bertrand Arnulf
Edgardo D Carosella
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2015
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-015-0114-8

Other articles of this Issue 1/2015

Journal of Hematology & Oncology 1/2015 Go to the issue

Research

Genetically modified "obligate" anaerobic Salmonella typhimurium as a therapeutic strategy for neuroblastoma

Research Article

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment

Review

Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia

Review

Drugging the unfolded protein response in acute leukemias

Research article

Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets

Research

Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits